Diagnostic X-Ray Systems

Royal Philips Electronics has introduced the Juno DRF and the DigitalDiagnost – ER Wireless systems. Introduced for the first time in the United States, the Juno DRF, a remote-controlled flat detector system, combines digital radiography and fluoroscopy applications in 1 system, enabling a wide range of applications. The system's dual imaging mode increases room utilization and enables faster workflow and increased patient throughput. The 2-in-1 system is capable of all common radiographic procedures, gastrointestinal studies, tomography, and vascular studies. Its unique Source Image Distance of 180 cm (71 in) and high table–weight capacity of up to 284 kg (626 lb), without any restrictions for movement, allows for diverse examinations and patient types. An optional stitching function and vascular imaging package also expand the system's capability.

By eliminating hardware and peripheral equipment, which typically hinder access to the patient, the DigitalDiagnost – ER Wireless radiography configuration eases access to critical patients in emergency departments, trauma units, and recovery bays. The rugged wireless portable detector with built-in handle and cable-free design enables simple maneuvering for even the most difficult anatomical views, allowing the system to be integrated seamlessly into the emergency department. The wireless portable detector also helps minimize the risk of interference with life-saving equipment.

For more information, contact Philips Electronics North America Corporation, 3000 Minuteman Rd, M/S 109, Andover, MA 01810; phone (800) 233-1828; www.usa.philips.com.

Foot and Ankle System

Extremity Medical, LLC announced it has received 510(k) clearance from the US Food and Drug Administration (FDA) for its IOFiX Intraosseous Fixation System for foot and ankle procedures. This comprehensive system provides a completely new method for delivering compression and stable fixation for fusion of many troublesome joints in the foot. The fixation system has been designed to fill a large void in foot and ankle surgery by applying the well-accepted principles of intramedullary fixation to offer the surgeon significantly improved modularity, ease of use, and construct rigidity. The IOFiX System requires small incisions and is capable of facilitating many surgical techniques involving trauma and reconstructive surgery of the forefoot, midfoot, and/or hindfoot—all in 1 set.

For more information, contact Extremity Medical, LLC, 300 Interpace Pkwy, Suite 410, Parsippany, NJ 07054; phone (973) 588-8980; fax (973) 316-9901; www.extremitymedical.com.

Bone-Targeted Therapy

Amgen Inc. has announced receiving FDA approval for XGEVA™ (denosumab), the first RANK Ligand inhibitor for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. XGEVA was approved following a 6-month priority review by the FDA—a designation reserved for drugs that offer major advances in treatment or provide a treatment where no adequate therapy exists. XGEVA is not indicated for the prevention of SREs in patients with multiple myeloma.

Bone metastases are a serious concern for patients with advanced cancer and present a considerable economic burden to the health care system. The primary goal of treatment for bone metastases is to prevent the occurrence of debilitating bone complications, which can disrupt a patient's life and cause disability, pain, and hospitalization.

The RANK Ligand pathway is believed to play a central role in cancer-induced bone destruction, regardless of cancer type. XGEVA is a fully human monoclonal antibody that binds to RANK Ligand, a protein essential for the formation, function, and survival of osteoclasts. XGEVA prevents RANK Ligand from activating its receptor, RANK, on the surface of osteoclasts, thereby decreasing bone destruction.

In clinical trials, fatigue/asthenia, hypophosphatemia, and nausea were the most common reported adverse reactions in patients taking XGEVA. Dyspnea was the most common serious adverse reaction reported. The drug also has caused severe hypocalcemia and osteonecrosis of the jaw.

To review the XGEVA prescribing information, visit www.amgen.com. For more information, contact Amgen Corporate Communications, Mailstop 28-1-C, One Amgen Center Dr, Thousand Oaks, CA 91320; phone (805) 447-1000; www.amgen.com.

The journal's New Products/Product News section does not evaluate or recommend products. The information published in this section is most often obtained from public news sources, including manufacturers' announcements.